HC Wainwright Issues Positive Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Corcept Therapeutics in a research note issued on Monday, May 4th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.02 per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.35 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.44 EPS, Q2 2027 earnings at $0.71 EPS, FY2027 earnings at $2.84 EPS, FY2028 earnings at $3.73 EPS, FY2029 earnings at $5.91 EPS and FY2030 earnings at $8.60 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same quarter last year, the business earned $0.17 earnings per share. Corcept Therapeutics’s revenue was up 4.9% on a year-over-year basis.

Several other brokerages also recently weighed in on CORT. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday, March 26th. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a report on Friday. Finally, Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and an average target price of $74.67.

Corcept Therapeutics Trading Down 0.5%

Shares of CORT opened at $51.37 on Wednesday. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $91.00. The stock has a fifty day moving average price of $39.47 and a 200-day moving average price of $54.18. The firm has a market cap of $5.51 billion, a PE ratio of 146.76 and a beta of 0.36.

Insider Buying and Selling

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total transaction of $819,400.00. Following the sale, the insider owned 2,231 shares in the company, valued at approximately $91,404.07. The trade was a 89.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joseph K. Belanoff sold 26,198 shares of the stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total value of $1,311,733.86. Following the completion of the transaction, the chief executive officer directly owned 2,918,326 shares in the company, valued at $146,120,582.82. This represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 66,198 shares of company stock worth $2,851,169 in the last 90 days. Insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $25,000. Advisory Services Network LLC acquired a new stake in shares of Corcept Therapeutics in the third quarter worth $25,000. Clearstead Advisors LLC raised its holdings in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the last quarter. Atlas Capital Advisors Inc. acquired a new position in Corcept Therapeutics during the fourth quarter valued at $31,000. Finally, Hantz Financial Services Inc. lifted its position in Corcept Therapeutics by 113.7% during the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 524 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.